Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae

被引:24
作者
Weiss, K [1 ]
Laverdiere, M [1 ]
Restieri, C [1 ]
机构
[1] Univ Montreal, Hop Maison Neuve Rosemont, Dept Infect Dis & Microbiol, Montreal, PQ H1T 2M4, Canada
关键词
D O I
10.1093/jac/42.4.523
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The principal aim of this study was to evaluate the in-vitro activity of new quinolones against clinical strains of Streptococcus pneumoniae. Four hundred and fifty-two single clinical isolates (of which 362 were susceptible to penicillin, 54 intermediate and 36 highly resistant) were tested against penicillin, cefuroxime, ciprofloxacin, levofloxacin, trovafloxacin and Bay 12-8039. Of the tested S. pneumoniae strains, 97.1% had MICs of trovafloxacin of less than or equal to 0.25 mg/L, and 96.7% had MICs of Bay 12-8039 of less than or equal to 0.25 mg/L (difference not statistically significant); 81.9% of strains had MICs of cefuroxime of less than or equal to 0.25 mg/L (P less than or equal to 0.001 against both quinolones). Only 4% and 0.7% of the strains had MICs of levofloxacin and ciprofloxacin respectively of less than or equal to 0.25 mg/L. Compared with older quinolones, trovafloxacin and Bay 12-8039 have good in-vitro activity against S. pneumoniae.
引用
收藏
页码:523 / 525
页数:3
相关论文
共 10 条
[1]   In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against and Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].
Brueggemann, AB ;
Kugler, KC ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1594-1597
[2]  
FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607
[3]   Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219) [J].
Kenny, GE ;
Cartwright, FD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :1048-1049
[4]  
MATSUMURA SO, 1997, 37 INT C ANT AG CHEM, P134
[5]  
National Committee for Clinical Laboratory Standards, 1997, M7A4 NCCLS
[6]   Levofloxacin in vitro activities bacteremic isolates of Streptococcus pneumoniae [J].
Plouffe, JF ;
Baird, I ;
Barnishan, J ;
PorterfieldBaxa, J ;
Best, M ;
Dalieh, S ;
Emerick, J ;
Fass, RJ ;
Gianakopoulos, G ;
Hackman, BA ;
Hadley, S ;
Herbert, M ;
Koletar, SL ;
Maher, W ;
Minor, JA ;
Oglevee, BA ;
Para, MF ;
Parsons, J ;
Rogers, T ;
ScottTibbs, G ;
Tumbleson, CS .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 25 (01) :43-45
[7]   USA RESISTANCE PATTERNS AMONG UTI PATHOGENS [J].
THOMSON, KS ;
SANDERS, WE ;
SANDERS, CC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 :9-15
[8]   Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae [J].
Thomson, KS ;
Chartrand, SA ;
Sanders, CC ;
Block, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :478-480
[9]   Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin [J].
Visalli, MA ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :1867-1870
[10]   Streptococcus pneumoniae resistance to fluoroquinolones [J].
Wise, R ;
Brenwald, N ;
Gill, M ;
Fraise, A .
LANCET, 1996, 348 (9042) :1660-1660